AIM 100 update – Camellia, Rhythmone and 4D Pharma

26th April 2018


Agriculture, engineering and food service conglomerate Camellia reported increased performance across the group in their final results, released 19th April. Revenues were up £41m to £298, with a bottom line of £28.6m, a turnaround from the previous years loss of £5.9m, helped by the £20m sale of subsidiary Duncan Lawrie.


Re-Branded RhythmOne recently reported a 71% revenue increase, with a 900% EBITDA uplift to $14m. The business, formerly known as Blinx, was spun out of Mike Lynch’s Autonomy. The stock suffered a disastrous year in 2014 after Benjamin Edelman noted that the business produced revenue-per-employee which was twice that of competitors, whilst questioning links to adware companies.

The group, who link advertisers to online platforms, was recently re-certified by the Trustworthy Accountability Group’s quality guidelines programme, designed to provide assurances to advertisers that their campaigns are placed in transparent and trustworthy environments. The group produced $21m cash from operations, and completed a $26m acquisition of YuMe.


Former AIM 100 Biotherapeutics Developer 4D Pharma announced final results on the 23rd April. The pre-revenue company are developing diagnostics and therapies for conditions related to the microbiota – the bodies bacteria, virus and fungi ecosystem. The company are focusing on solutions for IBS and Crohns disease, similar to another AIM listed company Shield therapeutics, who we shot a video for in late 2017.

4d also operate a 1,500 m2 manufacturing facility, allowing them to develop in-house, and scale up quickly when the time comes. Their recent results highlighted progression in clinical programmes, as well as growth of their intellectual property real-estate, now the largest in the microbiome sector. Cash burn for the year was almost £19m, with and end of year cash balance of £50m.